Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 10Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Skin Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Mycosis Fungoides 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Carcinoma, Basal Cell 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Sunitinib 4Cyclophosphamide 4Capecitabine 4Bevacizumab 4pazopanib 3Topotecan 3Paclitaxel 3Docetaxel 3Carboplatin 3temsirolimus 2liposomal doxorubicin 2fludarabine 2Sorafenib 2Panobinostat 2NVP-BKM120 2Lapatinib 2Irinotecan 2Immune Checkpoint Inhibitors 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Bortezomib 2vadimezan 1spartalizumab 1somatostatin receptor 2 1selinexor 1selicrelumab 1perifosine 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumors × cemiplimab × Clear all
NCT06651593 2026-05-06

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡